Medidata, a Dassault Systèmes brand and provider of clinical trial solutions to the life sciences industry, has contributed insights to a newly published whitepaper by the Singapore Clinical Research Institute (SCRI). The paper, titled “Advancing Clinical Trials with Decentralised Elements in Singapore: Opportunities, Readiness, and Scalable Adoption,” assesses Singapore’s readiness for clinical trials with decentralised elements and outlines a roadmap for their responsible, scalable adoption.
Drawing on its experience supporting more than 42,000 global trials and 13 million patients, Medidata contributed global perspectives and practical insights to the whitepaper’s assessment of Singapore’s current ecosystem readiness. The paper concludes that while Singapore is well-positioned for selective adoption of decentralised elements in hybrid trials, achieving system-wide readiness requires moving from ad-hoc institutional arrangements to a standardised, scalable national operating model.
“Decentralised elements are increasingly incorporated into global protocol design, but their adoption must be grounded in fit-for-purpose operational models, robust data governance, and scalable technology,” said Edwin Ng, General Manager, Asia Pacific, Medidata. “Drawing on Medidata’s experience across thousands of global studies, our unified platform technology can support connected workflows and auditable data integrity in trials with decentralised elements, alongside appropriate validation and operational oversight. We are proud to contribute these insights to SCRI’s whitepaper and to support sponsors, investigator sites, and patients in delivering safe, more accessible, and high-quality clinical research across Singapore and the broader region.”
To support Singapore’s transition from pilot implementations to scalable hybrid maturity, the whitepaper outlines several core national recommendations:
Unlocking value for Asia-Pacific clinical research
Through this collaboration, Medidata provided evidence-based insights to address bottlenecks across the clinical research ecosystem:
Singapore has established strong foundations in clinical research; the opportunity now is to build on these strengths through greater ecosystem collaboration that enables the appropriate use of decentralised